Moderna's Vaccine Success, Stock Performance Mixed

Modernas stock surged by 6.4% following a French study confirming the safety and effectiveness of its COVID-19 vaccine, but the increase is not seen as a game-changer due to the companys volatile stock history. Despite the recent boost, Modernas shares have declined by 34.5% this year and are currently trading at $27.52, a significant drop from its 52-week high. Long-term investors would see a return of just $172.51 on a $1,000 investment made five years ago, highlighting the considerable risk associated with the stock.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.